TACTIC project aims to uncover genetic causes of cancer and develop targeted therapies

NewsGuard 100/100 Score

Investigating the genetic causes of cancer and fighting them with new drugs: To this end, German Cancer Aid is funding the TACTIC project until 2028 with 11.8 million euros. A key element of the project: to cover all aspects of drug development, cancer research and drug development laboratories across Germany are joining forces to form a national center. Researchers from the Faculty of Medicine at the University of Duisburg-Essen are significantly involved in TACTIC.

The research consortium jointly led by the University of Duisburg-Essen (UDE), Prof. Dr. Christian Reinhardt, and the Universities of Frankfurt and Dortmund plans to specifically combat the genetic causes of cancer with newly developed active substances. In simple terms, transcription is a process in the cell nucleus in which genetic information is copied from our DNA and then used to build proteins. The researchers at TACTIC now aim to influence the transcription of those genes that are responsible for the development of cancer. However, it is crucial that other important transcription processes are not impaired in the process.

Within the TACTIC project, experts and laboratories in chemical biology, drug discovery and oncology are joining forces across Germany to form a national center. The consortium thus covers all steps of drug development, from screening and structural biology to medicinal chemistry and toxicological studies. The objective is to find promising active substances that can be further developed into drugs for clinical use.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel combination therapy shows promise in difficult-to-treat endometrial cancer, study finds